Yes it is mrblu,
The numbers associated with these early stage (prec-clin and Stage 1) deals is also encouraging.
The iNKT deals are good - particularly the Gilead/Kite collaboration with Appia. Appia wasn't too different to ALA before their company making deal.
I do notice that the iNKT deals were a couple of years ago and everything since has been T cell therapy based. But there are far more companies in the T-cell (and NK cell) therapies than iNKT.
Little pop in SP over the past couple of weeks has been good .
Yes it is mrblu, The numbers associated with these early stage...
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
-0.005(4.17%) |
Mkt cap ! $120.7M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 11.0¢ | $178.3K | 1.525M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 622434 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 56500 | 3 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
11.0¢ |
Change
-0.005 ( 8.33 %) |
||||
| Open | High | Low | Volume | ||
| 12.0¢ | 12.0¢ | 11.0¢ | 805232 | ||
| Last updated 15.27pm 04/06/2024 ? | |||||
| ALA (ASX) Chart |